

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 September 2025 (11.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/188901 A8

**(51) International Patent Classification:**

A61K 38/47 (2006.01) A61K 9/00 (2006.01)
A61K 47/68 (2017.01) A61K 31/4985 (2006.01)

(21) International Application Number:

PCT/US2025/018582

(22) International Filing Date:

05 March 2025 (05.03.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/561,701 05 March 2024 (05.03.2024) US
63/673,280 19 July 2024 (19.07.2024) US

(71) Applicant: **HALOZYME, INC.** [US/US]; 12390 El Camino Real, San Diego, CA 92130 (US).

(72) Inventors: **CONNOR, Robert**; c/o Halozyyme, Inc., 12390 El Camino Real, San Diego, CA 92130 (US). **KANG, David**; c/o Halozyyme, Inc., 12390 El Camino Real, San Diego, CA 92130 (US). **NEKOROSKI, Tara**; c/o Halozyyme, Inc., 12390 El Camino Real, San Diego, CA 92130 (US). **LABARRE, Michael**; c/o Halozyyme, Inc., 12390 El Camino Real, San Diego, CA 92130 (US).

(74) Agent: **SMYTH, Robert** et al.; 2222 Market Street, Philadelphia, PA 19103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:


02 October 2025 (02.10.2025)

(15) Information about Correction:

see Notice of 02 October 2025 (02.10.2025)

(54) Title: COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES

FIG. 1



(57) Abstract: Provided are combination dosing regimens comprising administering an antibody-drug conjugate and hyaluronidase. Combinations and compositions containing the antibody-drug conjugate and hyaluronidase are provided. The dosing regimens and combinations are for treating or preventing cancer.